The Treatment of Substance Use Disorders and Addiction During COVID-19 Series (ACMT- ASAM Collaboration)

4.29 (14 votes)

The Live Event Scheduled for 02/05/2021 at 1:00 PM (EST) has been Cancelled

Includes a Live Event on 03/05/2021 at 1:00 PM (EST)

  • Register
    • Non-Member - Free!
    • Regular Member - Free!
    • Retired - Free!
    • Early Career Physician - Free!
    • Resident - Free!
    • Student - Free!
    • Associate - Free!
    • ASAM Staff - Free!
    • International Member - Free!
    • Emeritus Member - Free!
    • Provisional Member - Free!
    • Fellow Member - Free!
    • Honorary Member - Free!
    • CRT Member - Free!
image

The Treatment of Substance Use Disorders and Addiction During COVID-19 (ACMT-ASAM)


As the leader in developing clinical guidelines and standards in addiction medicine, ASAM takes its responsibility very seriously. Many providers and programs are urgently working to mitigate risks related to COVID-19. From May through August 2020, the American College of Medical Toxicology (ACMT) recurring "3rd Friday Addiction Toxicology Case Conference" series is co-hosted by the American Society of Addiction Medicine (ASAM). The co-hosted series will be an interactive discussion of addiction toxicology cases and will feature ASAM and ACMT members, as well as guest experts. This series of sessions provides a comprehensive overview of COVID-19 resources and focuses on challenging cases to inform your practices during the pandemic. 

This co-hosted series has been extended to July 2021 and has also been moved to the 1st Friday of every month. 

By registering for this package, you will automatically receive reminder emails about upcoming webinars.

Series Dates: 

Friday, April 17, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, May 15, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, June 19, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, July 17, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, August 21, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)

Extended Series Dates: 
Friday, September 4, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, October 2, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, November 6, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, December 4, 2020 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, January 8, 2021 1:00 pm ET / 2:00 pm CT/ 10:00 am PT (On-Demand)
Friday, February 5, 2021 1:00 pm ET / 2:00 pm CT/ 10:00 am PT
Friday, March 5, 2021 1:00 pm ET / 2:00 pm CT/ 10:00 am PT
Friday, April 2, 2021 1:00 pm ET / 2:00 pm CT/ 10:00 am PT
Friday, May 7, 2021 1:00 pm ET / 2:00 pm CT/ 10:00 am PT
Friday, June 4, 2021 1:00 pm ET / 2:00 pm CT/ 10:00 am PT
Friday, July 2, 2021 1:00 pm ET / 2:00 pm CT/ 10:00 am PT

Previous Sessions

Watch on-demand versions of previous sessions in the contents tab. 

Learning Objectives

By completing these sessions, you will be able to:

  • Describe outcomes that lead to improvement in response perspectives on navigating challenges that arise during novel care delivery
  • Explain methods to navigate challenges that arise utilizing telehealth and phone support
  • Identify related changes in monitoring for patients treated for opioid use disorder and in novel settings
  • Recognize medication availability for patients treated for opioid use disorder and in novel settings
Moderators: 
    Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM (ACMT/ASAM Expert) Director of Toxicology and of the Toxicology Consult Service, University of Rochester Medical Center, Rochester, NY 
    Gloria J. Baciewicz, MD, FASAM Director, Addiction Psychiatry Program (called Strong Recovery Addiction Psychiatry Program); Medical Director, Adult Ambulatory Program for Strong Health; Professor of Clinical Psychiatry, Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 
Session 1: Friday, April 15, 2020
Speakers: 
    Gloria J. Baciewicz, MD Director, Addiction Psychiatry Program (called Strong Recovery Addiction Psychiatry Program); Medical Director, Adult Ambulatory Program for Strong Health; Professor of Clinical Psychiatry, Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 

    Chris Bundy, MD, MPH
    Associate Medical Director, Washington Physicians Health Program, Seattle, WA 

    Paul H. Earley, MD, DFASAM
    Addiction Medicine Physician; President,  American Society of Addiction Medicine; President, Federation of State Physician Health Programs, Atlanta, GA 

    Michael Holland, MD, FEAPCCT, FAACT, FACOEM, FACMT, FACEP
    Clinical Professor in the Department of Emergency Medicine, State University of New York (SUNY), Upstate Medical University; Senior Medical Toxicologist, CTEH, Syracuse, NY 

    JoAn Laes, MD
    Addiction Medicine Physician, Hennepin Healthcare, Minneapolis, MN 

    Lewis Nelson, MD
    Professor and Chair of Emergency Medicine, Rutgers University, Newark, NJ 

    Jeanmarie Perrone, MD, FACMT
    Professor of Emergency Medicine at the Hospital of the University of Pennsylvania; Director, Division of Medical Toxicology and Addiction Medicine Initiatives, Department of Emergency Medicine, University of Pennsylvania; Founding Director, Penn Medicine Center for Addiction Medicine and Policy, Philadelphia, PA 

    Myra Rodriguez, PAC
    Affiliate Member of the American Society of Addiction Medicine (ASAM); Director of Medical Affairs Huther Doyle Chemical Dependency Treatment Program, Rochester, NY 

    Ed Salsitz, MD, DFASAM
    Associate Clinical Professor of Psychiatry, Mount Sinai School of Medicine, Mount Sinai and Beth Israel Hospitals, New York, NY
Cases:
  1.  A colleague has identified some drug testing results from a professional monitoring program case and is requesting feedback.  
  2. A 31-year-old contacts an outpatient treatment program to receive treatment for opioid use disorder and has some challenges stabilizing via phone/telehealth contact.
  3. A detoxification facility was not able to admit a patient due to fever, cough, and presumed COVID19 positive test.  He is quarantined at a local hotel supported by county resources -a department of health representative has asked if 'ambulatory detox' for alcohol dependence could be arranged from an outpatient clinic to the hotel site supporting him
  4. A 44-year-old patient with a long history of opioid and stimulant use disorder has taken several doses of his  'two week' take-home quantity of methadone which he received due to COVID19 -he normally attends 6/7 days a week.  He is given naloxone by his partner and transported to the Emergency Department. 
Session 2: Friday, May 15, 2020
Speakers: 
    Gloria J. Baciewicz, MD (ASAM Expert)
    Director, Addiction Psychiatry Program (called Strong Recovery Addiction Psychiatry Program); Medical Director, Adult Ambulatory Program for Strong Health; Professor of Clinical Psychiatry, Department of Psychiatry, University of Rochester Medical Center, Rochester, NY

    Kenneth R. Conner, PsyD, MPH (Guest Expert)
    Co-Director, Center for the Study and Prevention of Suicide; Clinical Psychologist and Professor in Emergency Medicine and Psychiatry, University of Rochester Medical Center, Rochester, NY

    Robert K. Horowitz, MD (Guest Expert)
    Chief, Division of Palliative Care; Georgia and Thomas Gosnell Distinguished Professor in Palliative Care, University of Rochester Medical Center, Rochester, NY

    Ross Sullivan, MD (ACMT/ASAM Expert)
    Director of Medical Toxicology, Upstate University Hospital; Director, Upstate Emergency Medicine Opioid Bridge Clinic; Medical Director, Helio Health, Syracuse, NY

    Ingrid Vicas, MD (ACMT Expert)
    Clinical Associate Professor, Departments of Emergency Medicine, Internal Medicine, Physiology & Pharmacology, Cummings School of Medicine, University of Calgary, Alberta, Canada

    Melissa Weimer, DO, MCR, FASAM (ASAM Expert)
    Medical Director, Yale Addiction Medicine Consult Service (YAMCS); Assistant Professor, Yale School of Medicine, New Haven, CT
Cases:
  1. A 58-year-old M with opioid use disorder treated with 8/2 mg buprenorphine/naloxone two films/day is diagnosed with nephrolithiasis after an emergency trip to the hospital. 
  2. A 60-year-old F who, under normal circumstances, receives 2 weeks RX but since the COVID-19 pandemic has received 30 days RX to minimize travel and contact with the pharmacy. She calls 8 days early reporting she is "out."
  3. A 22-year-old F with alcohol use disorder, who has increased her drinking since the COVID-19 pandemic, reaches out for help. 
Session 3: Friday, June 19, 2020
Speakers: 
    Alexandra Amaducci, DO (ACMT Expert)
    Emergency Medicine Physician, Lehigh Valley Hospital Muhlenberg, Bethlehem, PA

    Matthew D. Cook, DO (ACMT Expert)
    Chief, Division of Medical Toxicology, Department of Emergency And Hospital Medicine, Lehigh Valley Health Network, Allentown, PA

    Brian Hurley, MD, MBA, DFASAM (ASAM Expert)
    Director of Addiction Medicine, Los Angeles County Department of Health Services, Los Angeles, CA

    Ryan J. Magnuson, DO (Guest Expert)
    Assistant Professor, Department of Medicine, Pulmonary Diseases and Critical Care, University of Rochester Medical Center, Rochester, NY

    Kelly S. Ramsey, MD, MPH, MA, FACP (ASAM Expert)
    President-Elect, New York Society of Addiction Medicine (NYSAM)

    Henry D. Swoboda, MD (ACMT/ASAM Expert)
    Assistant Professor, Department of Emergency Medicine, Rush University Medical College, Chicago, IL
Cases:
  1. A 47-year-old M furloughed during COVID19 has been drinking heavier and after trying to ‘self-detox’ presents to the ED with tachycardia, hypertension, tremors and hallucinations. 
  2. An Intensivist asks if there is utility in using buprenorphine and some ‘other’ techniques for some of the severe, critically ill, COVID19 patients that often require prolonged sedation and analgesia.
  3. A 29-year-old F with opioid and stimulant use disorder and IVDU-associated severe aortic valve endocarditis with perforation and severe aortic regurgitation is hospitalized during COVID19 – she is not complying with treatments/regimens critical to success with valve replacement. 
Session 4: Friday, July 17, 2020
Speakers: 
    Carolyn W. Greer, MS, MD, FACOG, FASAM(ASAM Expert)
    Addiction Medicine Specialist, Otis R. Bowen Center for Human Services; Medical Director, Bowen Recovery Center, Fort Wayne, IN

    Jonathan C. Lee, MD, MBA, FASAM, FACP, FAPA (ASAM Expert)
    Addiction Medicine Physician, Medical Director, The Farley Center, Williamsburg, VA; Community Assistant Professor, Eastern Virginia Medical School, Norfolk, VA

    Lewis Nelson, MD, FACMT (ACMT Expert)
    Chair of the Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, NJ

    Alaina R. Steck, MD, FACMT (ACMT Expert)
    Assistant Professor of Emergency Medicine, Emory University School of Medicine, Atlanta, GA

Cases:
  1. A 60 -year-old administrator requests ambulatory detoxification for combined alcohol and sedative dependence during COVID19. He has several previous detoxification and treatment episodes that have required aggressive treatment regimens to get his withdrawal under control in the past. 
  2. A Professional Health Program identifies a physician who is dependent on kratom and has considerations about treatment regimen and drug testing/monitoring.
  3. A 31-year-old F, 30 weeks pregnant, is found unconscious behind an abandoned house. She has had limited prenatal care and reportedly been using substantial amounts of ‘street Xanax,” fentanyl, alcohol and cocaine. She is intubated for airway and breathing support and is waking up agitated, requiring “huge doses of sedatives.” The Intensivists and OB are asking for assistance managing her dependence, withdrawal and sedation requirements.

Session 5: Friday, August 21, 2020
Speakers: 
    Lewis Nelson, MD, FACMT (ACMT Expert)
    Chair of the Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, NJ

    Neil S. Seligman, MD, MS (Guest Expert)
    Director, Labor & Delivery, Highland Hospital; Associate Professor, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY   

    Jeffrey Selzer, MD, DFASAM, DFAPA (ASAM Expert)
    Medical Director, Committee for Physician Health, Medical Society of the State of New York Director, Physician’s Resource Network, Northwell Health, Albany, NY

    Norman W. Wetterau, MD, FAAFP, FASAM (ASAM Expert)
    Addiction Medicine Specialist, Tricounty Family Medicine; Clinical Assistant Professor of Family Medicine, University of Rochester School of Medicine, Rochester, NY
Cases:
  1. A 27-year-old M presents to the ED with cellulitis from IVDU. He had relapsed with fentanyl and cocaine in April 2020 as a month Rx his pharmacy changed to delivering all medication early in the COVID-19 pandemic and his Rx was “stolen”. He’d gone without buprenorphine/naloxone for several days and, unable to contact his clinic, he’d used heroin/fentanyl then was, “just back at it....” Interested in getting back into treatment and restarting buprenorphine/naloxone as soon as possible.
  2. A 38-year-old M is interested in getting help for stimulant and opioid use but the inpatient program he’d wanted to enter is “holding admits due to a COVID19 outbreak,” and there is a two-week wait for either telemedicine or on-site evaluation at the county treatment program in a rural part of the state. After 3 days of trying to “detox at home,” he presents to the Emergency Department because, “I didn’t know what else to do.” Patient is in florid opioid withdrawal with rhinorrhea, tearing, yawns repeatedly, has vomiting and diarrhea and is extremely anxious and restless.
Session 6: Friday, September 4, 2020
Speakers: 
    Michael Hodgman, MD (ACMT Expert)
    Assistant Professor of Emergency Medicine, Upstate Medical University, Syracuse, NY

    John A. Hopper, MD, DFASAM, FAAP, FACP (ASAM Expert)
    Clinical Professor, Wayne State University School of Medicine, Detroit, MI

    JoAn Laes, MD (ACMT Expert)
    Attending Physician, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN

    Barry K. Logan, PhD, F-ABFT (Guest Expert)
    Executive Director, Center for Forensic Science Research and Education, Fredric Rieders Family Renaissance Foundation; Senior Vice President of Forensic Sciences, Chief Scientist, NMS Labs, Willow Grove, PA

Cases:
  1. This case features a patient with combined opioid and sedative use disorder who has stabilized on buprenorphine without opioid use for years but has continued to use benzodiazepines and other sedatives.
  2. A 44-year-old F is found acting bizarre and agitated. She has psychomotor agitation and bizarre 'rocking' movements and is markedly tachycardic and sweating profusely. She is on probation and has numerous legal issues related to substance use.
  3. This case involves discussion of the different types of synthetic opioids found in the heroin supply and differences in pharmacology that would, in particular, impact the ability to start buprenorphine.
Session 7: Friday, October 2, 2020
Speakers: 
    Barry K. Logan, PhD, F-ABFT (Guest Expert)
    Executive Director, Center for Forensic Science Research and Education, Fredric Rieders Family Renaissance Foundation; Senior Vice President of Forensic Sciences, Chief Scientist, NMS Labs, Willow Grove, PA

    Soumya L. Pandalai, MD, FACP, FASAM (ACMT Expert)
    Clinical Assistant Professor, University of Arizona College of Medicine; Banner University Medical Center Phoenix (BUMCP) Addiction Medicine, Phoenix, AZ

    Andrew Stolbach, MD, MPH, FAACT, FACEP, FACMT (ACMT Expert)
    Associate Professor of Emergency Medicine, Department of Emergency Medicine, Johns Hopkins University School of Medicine; Johns Hopkins Hospital, Baltimore, MD
Cases:
  1. This case will feature discussion of drug-induced agitated delirium with experts dissecting the mechanism and common course of events that occur in the most severe type of agitated delirium, often referred to as Excited Delirium Syndrome. Myths and misperceptions in care of patients with agitation and delirium will be addressed, as will discussion of the appropriate use of sedation and importance of cooling in these patients. Case discussion will also include an overview of causes of agitated delirium, including the types of drugs involved as well as non-drug mechanisms.  
  2. This case includes an example of how an outpatient clinical addiction medicine program's clinical services were impacted by protests related to the death of George Floyd, and serves to highlight the need for flexibility, including telemedicine support, in order to rapidly respond to stresses at various levels of addiction care brought on by COVID-19 and other factors. Social and racial disparities in addiction medicine, exacerbated by COVID-19, will also be discussed to provide examples of successful methods used to keep access to critical services and support, including critical medications to treat opioid use disorder in particular.  
Session 7: Friday, November 6, 2020
Speakers: 
    Derek Eisnor, MD (ACMT/ASAM Expert)
    Medical Officer, Division of Clinical Development, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC

    Lewis S. Nelson, MD, FACMT, FASAM (ACMT/ASAM Expert)
    Professor and Chair of Emergency Medicine, Rutgers New Jersey Medical School, Newark, NJ

    Natalie Neumann, MD (Guest Expert)
    Clinical Instructor, Department of Emergency Medicine, Yale School of Medicine, Yale University, New Haven, CT

    Marc T. Swogger, PhD (Guest Expert)
    Associate Professor, Department of Psychiatry, Unversity of Rochester Medical Center, Rochester, NY
Cases:
  1. A 28-year-old F with polysubstance dependence, including a history of heroin/fentanyl, cocaine, cannabis, prescription benzodiazepines and stimulant (both amphetamines and methylphenidate) use, is currently receiving buprenorphine/naloxone in an outpatient addiction treatment program. She is interested in attending a “ketamine clinic” for depression.” She had undergone a “very positive” ayahuasca experience a few years prior, traveling to Brazil to do so, but it wore off and she is hoping her response to ketamine will be similar but more sustained. 
  2. A 32-year-old F with alprazolam dependence is found unresponsive after insufflating “some Percocets.” Transient hemodynamic response to IN naloxone but she does not wake up. In order to appropriately ventilate and control agitation, she requires 250 mcg/hour fentanyl, 8 mg/hour midazolam and 2 mg/kg/minutes of ketamine. Also, shortly after admission, the ICU team is contacted by the patient's mother who says she’d been informed that her daughter had been in contact with a person who’d been diagnosed with COVID-19.  
Session 7: Friday, December 4, 2020
Speakers: 
    Lewis S. Nelson, MD, FACMT, FASAM (ACMT/ASAM Expert)
    Professor and Chair of Emergency Medicine, Rutgers New Jersey Medical School, Newark, NJ

    Cara Poland, MD, M.Ed, FACP, DFASAM  (ASAM Expert)
    Assistant Professor, College of Human Medicine, Michigan State University, Grand Rapids, MI

    Ross Sullivan, MD (ACMT/ASAM Expert)
    Director of Medical Toxicology, Upstate University Hospital; Director, Upstate Emergency Medicine Opioid Bridge Clinic; Medical Director, Helio Health, Syracuse, NY
Cases:
  1. A 26-year-old F with opioid use disorder ‘reconnects’ with an outpatient treatment program “to get back on Suboxone and then get the shot.” She has a history of fentanyl use disorder with use, despite Rx of buprenorphine/naloxone. Also, UDS showed her to stop taking, or only intermittently take, the buprenorphine around her fentanyl use. At the start of COVID-19, the plan was to have sufficient obs doses and on-site dosing to safely give the SC buprenorphine, but she didn’t follow-up. “Now I’m ready.” This case features discussion of buprenorphine induction and stabilization in order to safely give the SC buprenorphine monthly injection. Drug testing during COVID-19 as well as supporting challenging patients with limited ‘on-site’ resources will be discussed. On the on-site obs dose, the patient was caught taking a piece of buprenorphine/naloxone film pre-wrapped with cellophane, which she reported “was an accident. I had it open and didn’t want to lose it, so I wrapped it up.” 
  2. A 27-year-old F and mother of 3-year-old with Autism has been taking buprenorphine/naloxone but struggles with heavy crack cocaine use. Her partner is also struggling with cocaine and there have been several domestic disturbance calls as well as CPS calls to their residence. Counseling appointments have been challenging to make and, apparently, quite a few of the “early intervention” appointments for her son have been missed. CPS is asking for drug testing results. COVID-19 cases are increasing dramatically in the area.
Session 8: Friday, January 8, 2021
Speakers: 
    Arianna Sampson Campbell, PA-C (Guest Expert)
    Director, Co-Principal Investigator, California Bridge, Placerville, CA

    Frank J. Edwards, MD, FACEP (Guest Expert)
    GME Research Director, Associate Designated Institutional Official, Arnot Health Graduate Medical Education, Arnot Ogden Medical Center, Elmira, NY

    Eric J. Hill, CADC-I (Guest Expert)
    Substance Use Navigator, Emergency Department, Marshall Medical Center, Placerville, CA

    Nicholas Nacca, MD (ACMT Expert)
    Assistant Professor Emergency Medicine, University of Rochester Medical Center, Rochester, NY

    Ross Sullivan, MD (ACMT/ASAM Expert)
    Director of Medical Toxicology, Upstate University Hospital; Director, Upstate Emergency Medicine Opioid Bridge Clinic; Medical Director, Helio Health, Syracuse, NY
Cases:
  1. A 27-year-old M presents to the ED with cellulitis from IVDU. He had relapsed with fentanyl and cocaine in April 2020 as a month Rx his pharmacy changed to delivering all medication early in the COVID-19 pandemic and his Rx was “stolen”. He’d gone without buprenorphine/naloxone for several days and, unable to contact his clinic, he’d used heroin/fentanyl then was, “just back at it....” Interested in getting back into treatment and restarting buprenorphine/naloxone as soon as possible.
  2. A 38-year-old M is interested in getting help for stimulant and opioid use but the inpatient program he’d wanted to enter is “holding admits due to a COVID19 outbreak,” and there is a two-week wait for either telemedicine or on-site evaluation at the county treatment program in a rural part of the state. After 3 days of trying to “detox at home,” he presents to the Emergency Department because, “I didn’t know what else to do.” Patient is in florid opioid withdrawal with rhinorrhea, tearing, yawns repeatedly, has vomiting and diarrhea and is extremely anxious and restless.

Credits and Disclosures


Please Note: CME is available for the ACMT webinars between April 2020 and January 8, 2021. Certificates of attendance are available for Case Conferences held after January 8, 2021

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring activity for a maximum of 10 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAADAC, the Association for Addiction Professionals

This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification


American Board of Preventive Medicine (ABPM)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 10 LLSA credit towards ABPM MOC Part II requirements.

American Board of Anesthesiology (ABA)

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 10 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Psychiatry and Neurology (ABPN)

Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

American Board of Addiction Medicine (ABAM)

Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

CME Reviewer and Disclosure Information


ASAM CME Committee Reviewer

Edwin A. Salsitz, MD, DFASAM 

Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ACCME’s Policy For Disclosures During The COVID-19 Pandemic

Per ACCME’s simplified process for COVID-19, the requirement of disclosure of relevant financial relationships and resolution of personal conflicts of interest has been removed. Currently, there are no FDA-approved vaccines or treatments for COVID-19. Hence, there is no possibility of a relevant financial relationship that would create a conflict of interest.

Faculty and Panelists


See the list of moderators and panelists on the Speakers & Cases tab.

Key:

Complete
Failed
Available
Locked
April 17th 2020 ACMT/ASAM Addiction Toxicology Case Conference
April 17 2020 On-Demand
Open to view video.
Open to view video. This session was recorded on April 17th, 2020
April 17 2020 Slides
Open to download resource.
Open to download resource.
CME Quiz (April 21)
3 Questions  |  10 attempts  |  2/3 points to pass
3 Questions  |  10 attempts  |  2/3 points to pass
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
May 15th 2020 ACMT/ASAM Addiction Toxicology Case Conference
May 15th 2020 On-Demand
Open to view video.
Open to view video. This webinar was recorded on May 15, 2020.
May 15th 2020 Slides
Open to download resource.
Open to download resource.
CME Quiz (May 15)
3 Questions  |  10 attempts  |  2/3 points to pass
3 Questions  |  10 attempts  |  2/3 points to pass
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
June 19th 2020 ACMT/ASAM Addiction Toxicology Case Conference
June 19th 2020 On-Demand
Open to view video.
Open to view video. This webinar was recorded on June 19th, 2020.
June 19th 2020 Slides
Open to download resource.
Open to download resource.
CME Quiz (June 19)
3 Questions  |  10 attempts  |  2/3 points to pass
3 Questions  |  10 attempts  |  2/3 points to pass
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
July 17th 2020 ACMT/ASAM Addiction Toxicology Case Conference
July 17 2020 On-Demand
Open to view video.
Open to view video. This webinar was recorded on July 17th, 2020.
July 17 2020 Slides
Open to download resource.
Open to download resource.
CME Quiz (July 17)
3 Questions  |  10 attempts  |  2/3 points to pass
3 Questions  |  10 attempts  |  2/3 points to pass
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
August 21st 2020 ACMT/ASAM Addiction Toxicology Case Conference
August 21 2020 On-Demand
Open to view video.
Open to view video.
August 21 Slides
Open to download resource.
Open to download resource.
CME Quiz (August 21)
3 Questions  |  10 attempts  |  2/3 points to pass
3 Questions  |  10 attempts  |  2/3 points to pass
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
September 4 2020 ACMT/ASAM Addiction Toxicology Case Conference
September 4 2020 On-Demand
Open to view video.
Open to view video.
September 4 2020 Slides
Open to download resource.
Open to download resource.
CME Quiz (September 4)
3 Questions  |  10 attempts  |  2/3 points to pass
3 Questions  |  10 attempts  |  2/3 points to pass
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
October 2 2020 ACMT/ASAM Addiction Toxicology Case Conference
October 2 2020 On-Demand
Open to view video.
Open to view video.
October 2 2020 Slides
Open to download resource.
Open to download resource.
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
November 6 2020 ACMT/ASAM Addiction Toxicology Case Conference
November 6 2020 On-Demand
Open to view video.
Open to view video.
November 6 2020 Slides
Open to download resource.
Open to download resource.
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
December 4 2020 ACMT/ASAM Addiction Toxicology Case Conference
December 4 2020 On-Demand
Open to view video.
Open to view video.
December 4 2020 Slides
Open to download resource.
Open to download resource.
Credit and Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This webinar has been approved for 1 AMA PRA Category 1 Credit.
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
January 8 2021 ACMT/ASAM Addiction Toxicology Case Conference
January 8 2021 On-Demand
Open to view video.
Open to view video.
January 8 2021 Slides
Open to download resource.
Open to download resource.
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available Beginning in January 2021, this session was not approved for credit. You can print a certificate of completion for your records.
February 5 2021 ACMT/ASAM Addiction Toxicology Case Conference
February 5 2021 Live Webinar
This Live Component has been cancelled.
March 5 2021 ACMT/ASAM Addiction Toxicology Case Conference
March 5 2021 Live Webinar
03/05/2021 at 1:00 PM (EST)   |  60 minutes
03/05/2021 at 1:00 PM (EST)   |  60 minutes You will need to register for the webinar again through ACMT's link to receive your join information.
Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available Beginning in January 2021, this session was not approved for credit. You can print a certificate of completion for your records.
April 2 2021 ACMT/ASAM Addiction Toxicology Case Conference
April 2 2021 Live Webinar
04/02/2021 at 1:00 PM (EDT)   |  60 minutes
04/02/2021 at 1:00 PM (EDT)   |  60 minutes You will need to register for the webinar again through ACMT's link to receive your join information.
Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available Beginning in January 2021, this session was not approved for credit. You can print a certificate of completion for your records.
May 7 2021 ACMT/ASAM Addiction Toxicology Case Conference
May 7 2021 Live Webinar
05/07/2021 at 1:00 PM (EDT)   |  60 minutes
05/07/2021 at 1:00 PM (EDT)   |  60 minutes You will need to register for the webinar again through ACMT's link to receive your join information.
Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available Beginning in January 2021, this session was not approved for credit. You can print a certificate of completion for your records.
June 4 ACMT/ASAM Addiction Toxicology Case Conference
June 4 2021 Live Webinar
06/04/2021 at 1:00 PM (EDT)   |  60 minutes
06/04/2021 at 1:00 PM (EDT)   |  60 minutes You will need to register for the webinar again through ACMT's link to receive your join information.
Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available Beginning in January 2021, this session was not approved for credit. You can print a certificate of completion for your records.
July 2 2021 ACMT/ASAM Addiction Toxicology Case Conference
July 2 2021 Live Webinar
07/02/2021 at 1:00 PM (EDT)   |  60 minutes
07/02/2021 at 1:00 PM (EDT)   |  60 minutes You will need to register for the webinar again through ACMT's link to receive your join information.
Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available Beginning in January 2021, this session was not approved for credit. You can print a certificate of completion for your records.